# COHANCE (COHANCE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/cohance

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹438.5
- Change: -0.33%
- As of: 2026-09-18
- 1D return: -0.44%
- 5D return: -1.64%
- 1M return: -7.90%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, COHANCE is trading at ₹438.0, facing a mixed technical picture across different timeframes. The daily timeframe shows a bearish trend, with the price below its 20-day and 50-day Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs), though it remains above the 200-day SMA and the daily Supertrend indicator. This suggests short-term weakness. In contrast, the weekly timeframe indicates a bullish Supertrend, but the price is below its 20-day and 50-day EMAs and SMAs, signaling potential consolidation or a pullback within a broader upward move. The monthly timeframe presents a bearish Supertrend, with the price below this indicator, indicating significant long-term downward pressure. Recent patterns include an active daily Harami and a weekly Doji, suggesting potential indecision. The stock's current position is near the ₹438.17 pivot resistance level, with immediate support identified around ₹429.83.

- Daily trend shows weakness with price below short-term moving averages (20-day EMA/SMA, 50-day EMA/SMA).
- Weekly trend shows a bullish Supertrend, but price is below short-term moving averages, indicating potential conflict.
- Monthly trend is bearish, with the price below the monthly Supertrend.
- Nearest resistance is at the ₹438.17 pivot level, with support near ₹429.83.
- Active daily Harami and weekly Doji patterns suggest potential price indecision.

- Doji
- Harami
- Inside Bar

### News Context

Cohance Lifesciences announced significant strategic investments on September 3, 2026, aimed at bolstering its Antibody-Drug Conjugate (ADC) capabilities. The company plans to acquire an additional stake in NJ Bio, Inc. for approximately USD 13 million, increasing its ownership from 56% to 67.3%. Concurrently, Cohance will invest approximately USD 5 million to acquire a 65% controlling interest in Aruka Bio, Inc. Both transactions, funded by internal accruals, are expected to be completed by the end of September 2026, subject to definitive agreements and regulatory approvals. The company also confirmed its management's participation in upcoming investor events, including the JP Morgan India Conference on September 22, 2026, and a roadshow in Hyderabad on September 24, 2026. Cohance stated that no unpublished price-sensitive information would be disclosed during these interactions. On September 17, 2026, the company held its 8th Annual General Meeting, where shareholders approved the adoption of financial statements and the reappointment of Ms. Shweta Jalan as a director. All resolutions passed with over 99.97% of votes in favor.

- On September 3, 2026, Cohance Lifesciences announced plans to invest USD 13 million in NJ Bio, Inc. to raise its stake to 67.3%, and USD 5 million for a 65% controlling interest in Aruka Bio, Inc., funded by internal accruals.
- The company confirmed on September 17, 2026, that its management will attend the JP Morgan India Conference on September 22, 2026, and a roadshow in Hyderabad on September 24, 2026, with no unpublished price-sensitive information to be shared.
- Cohance Lifesciences held its 8th Annual General Meeting on September 17, 2026, where all ordinary resolutions, including financial statement adoption and director reappointment, were passed with over 99.97% shareholder approval.
- The USFDA inspection at Cohance Lifesciences was completed, as announced on September 4, 2026.

- Cohance Lifesciences Limited has informed the Exchange about Schedule of Analysts/ Institutional Investors Meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Cohance Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting
- Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection |SUBJECT: General Updates
- Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026. |SUBJECT: Committee Meeting Updates
- Cohance Lifesciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Press Release ". |SUBJECT: Press Release

### What Changed

On September 17, 2026, Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) held its 8th Annual General Meeting (AGM) via video conferencing. During the meeting, shareholders approved three ordinary resolutions, including the adoption of financial statements and the reappointment of Ms. Shweta Jalan as a director. The voting results, confirmed by a Scrutinizer's Report dated September 17, 2026, showed over 99.97% of votes cast in favor of each resolution. The company's stock closed at ₹438.0 on September 18, 2026, a slight decrease from its previous closing price of ₹439.95.

- Cohance Lifesciences Limited held its 8th AGM on September 17, 2026, with all ordinary resolutions passed by a significant majority (over 99.97% of votes cast).
- Key resolutions passed included the adoption of standalone and consolidated financial statements and the reappointment of Ms. Shweta Jalan as a director.
- A Scrutinizer's Report dated September 17, 2026, confirmed the voting outcomes.
- The company's stock closed at ₹438.0 on September 18, 2026, down from ₹439.95 on the previous trading day.

- Cohance Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting

### Official Filings

Cohance Lifesciences Limited has announced two strategic investments aimed at strengthening its Antibody-Drug Conjugate (ADC) strategy. The company's Investment, Banking and Authorisations Committee approved acquiring an additional stake in NJ Bio, Inc. for approximately USD 13 million, increasing its ownership from 56% to 67.3%. Concurrently, Cohance will invest approximately USD 5 million in Aruka Bio, Inc. to secure a 65% controlling interest. These transactions, funded by internal accruals, are expected to be completed by the end of September 2026, subject to definitive agreements and regulatory approvals. The company also reported the completion of a USFDA inspection, though details were not provided. In other developments, Cohance Lifesciences held its 8th Annual General Meeting on September 17, 2026, where shareholders approved all ordinary resolutions, including the adoption of financial statements and the reappointment of Ms. Shweta Jalan as a director. The company also disclosed its integrated annual report for FY26, showing consolidated revenue of ₹22.68 billion and adjusted EBITDA of ₹4.8 billion, with a gross margin of 70.8%. The report also highlighted progress in sustainability, with a 20% reduction in Scope 1 and 2 emissions against the FY23 baseline. Separately, the company submitted its Business Responsibility and Sustainability Report (BRSR) for FY25-26, detailing a paid-up capital of ₹38,25,67,140 and exports contributing 84% of its turnover. The BRSR also noted a 16.9% reduction in total energy intensity and an 18.9% decline in GHG emission intensity. A compounding fee of ₹8,29,88,900 was paid to the Reserve Bank of India related to foreign investments in ZCL Chemicals Limited.

- On September 3, 2026, Cohance Lifesciences approved acquiring an additional 244,587 shares of NJ Bio, Inc. for approximately USD 13 million, increasing its stake to 67.3%.
- On September 3, 2026, Cohance Lifesciences approved subscribing to Aruka Bio, Inc. shares for approximately USD 5 million to acquire a 65% controlling interest.
- Both investments are funded through internal accruals and are expected to be completed by the end of September 2026.
- Cohance Lifesciences held its 8th Annual General Meeting on September 17, 2026, where all ordinary resolutions, including financial statement adoption and director reappointment, were passed with over 99.97% of votes in favor.
- For FY26, the company reported consolidated revenue of ₹22.68 billion and adjusted EBITDA of ₹4.8 billion, with a gross margin of 70.8%.
- The BRSR for FY25-26, submitted on August 26, 2026, reported a paid-up capital of ₹38,25,67,140 and exports contributing 84% of total turnover.

- Cohance Lifesciences Limited has informed the Exchange about Schedule of Analysts/ Institutional Investors Meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Cohance Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting
- Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection |SUBJECT: General Updates
- Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026. |SUBJECT: Committee Meeting Updates
- Cohance Lifesciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Press Release ". |SUBJECT: Press Release
- Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Cohance Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Cohance Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on 17 September 2026 |SUBJECT: Shareholders meeting
- Cohance Lifesciences Limited has informed the Exchange about Integrated Annual Report 2026 |SUBJECT: General Updates
- Cohance Lifesciences Limited has informed the Exchange about submission of BRSR |SUBJECT: General Updates

### Fundamentals

Cohance Lifesciences reported a decline in its financial performance for Q1 FY2026-27. Revenue from operations decreased to ₹422.26 crore, down from ₹619.12 crore in the preceding quarter (Q4 FY2025-26) and ₹544.55 crore in the same quarter of the previous year (Q3 FY2025-26). This revenue contraction coincided with a shift to a loss for the period, with Profit Loss For Period recorded at -₹45.19 crore in Q1 FY2026-27, compared to a profit of ₹8.31 crore in Q4 FY2025-26 and ₹29.02 crore in Q3 FY2025-26. The company also reported a Profit Before Tax of -₹42.87 crore for Q1 FY2026-27, a significant drop from ₹19.91 crore in Q4 FY2025-26 and ₹40.60 crore in Q3 FY2025-26. While Finance Costs saw a reduction to ₹6.74 crore in Q1 FY2026-27 from ₹9.19 crore in Q4 FY2025-26, this was insufficient to offset the revenue decline and other operating expenses, which stood at ₹167.86 crore in Q1 FY2026-27. Tax Expense for the period was ₹2.32 crore. Investors should monitor revenue trends and the company's ability to return to profitability in upcoming quarters.

- Revenue From Operations for Q1 FY2026-27 was ₹422.26 crore.
- Profit Loss For Period in Q1 FY2026-27 was -₹45.19 crore.
- Profit Before Tax in Q1 FY2026-27 was -₹42.87 crore.
- Finance Costs in Q1 FY2026-27 were ₹6.74 crore.
- Other Expenses in Q1 FY2026-27 were ₹167.86 crore.

### Bull Case

The company's stock is currently trading above its 200-day Simple Moving Average (SMA) of ₹421.39 as of September 18, 2026, indicating a potentially positive long-term trend. On a weekly basis, the Supertrend indicator is bullish, and the 20-day Exponential Moving Average (EMA) shows a positive slope over the last 5 periods, suggesting some short-term upward momentum. The stock has also experienced positive returns over the last 3 and 6 months, with a 6-month return of 0.43.

- As of September 18, 2026, the stock price of ₹438.0 is above the 200-day SMA of ₹421.39.
- The weekly Supertrend indicator is bullish.
- The 20-day EMA slope over 5 periods on a daily chart is positive.
- The stock has generated a return of 0.43 over the past 6 months and 0.06 over the past 3 months.

### Bear Case

Cohance Lifesciences' stock performance shows signs of caution, particularly over longer timeframes. While the weekly trend indicates a bullish Supertrend, the monthly trend is bearish. The stock has experienced a significant decline of -52% over the past year and -59% since its inception, suggesting sustained downward pressure. Current technical indicators show the daily close at ₹438.0 is below its 20-day Exponential Moving Average (EMA) of ₹444.67 and its 50-day Simple Moving Average (SMA) of ₹443.49, with negative slopes on these averages, indicating a weakening short-term trend. The stock is trading near its immediate pivot resistance level of ₹438.17. Furthermore, the company's risk profile includes a substantial current drawdown of -60% and a maximum drawdown of -75%, highlighting significant historical volatility and potential for large price swings.

- The stock has declined by -52% over the past year and -59% since inception as of 2026-09-18.
- The monthly trend shows a bearish Supertrend, contrasting with a bullish weekly Supertrend.
- The daily closing price of ₹438.0 is below the 20-day EMA (₹444.67) and 50-day SMA (₹443.49), with negative slopes on these averages.
- The company has experienced a current drawdown of -60% and a maximum drawdown of -75%.

### FAQs

**What recent strategic investments has Cohance Lifesciences made to strengthen its ADC strategy?**

On September 3, 2026, Cohance Lifesciences announced two transactions to enhance its Antibody-Drug Conjugate (ADC) strategy. The company approved acquiring an additional 244,587 shares of NJ Bio, Inc. for approximately USD 13 million, increasing its stake from 56% to 67.3%. Additionally, it approved subscribing to Aruka Bio, Inc. shares for approximately USD 5 million to acquire a 65% controlling interest. Both investments are funded through internal accruals and were expected to be completed by the end of September 2026, subject to definitive agreements and regulatory approvals.

**What was the outcome of Cohance Lifesciences' 8th Annual General Meeting on September 17, 2026?**

Cohance Lifesciences (formerly Suven Pharmaceuticals Limited) held its 8th Annual General Meeting on September 17, 2026. Three ordinary resolutions were presented and passed with over 99.97% of votes in favor. These resolutions included the adoption of standalone and consolidated financial statements and the reappointment of Ms. Shweta Jalan as a director.

**What is the current technical trend for Cohance Lifesciences based on daily indicators as of September 18, 2026?**

As of September 18, 2026, daily technical indicators suggest a mixed trend. The Supertrend indicator is 'bullish' at 413.34, while the 20-day Exponential Moving Average (EMA) is 444.67, and the 50-day EMA is 442.92. The closing price was ₹438.0. The Average Directional Index (ADX) is 29.03, indicating some trend strength, with Plus DI at 21.81 and Minus DI at 19.36.

**How has Cohance Lifesciences' stock performed over different periods leading up to September 18, 2026?**

As of September 18, 2026, Cohance Lifesciences' stock has experienced varied returns across different timeframes. It showed a positive return of 0.06 over 3 months and 0.43 over 6 months. However, it recorded negative returns of -0.04 over 1 month, -0.08 over 20 days, -0.05 over 10 days, -0.02 over 5 days, -0.16 year-to-date, and a significant -0.52 over the past year. The return since the start of trading was -0.59.

- Cohance Lifesciences Limited has informed the Exchange about Schedule of Analysts/ Institutional Investors Meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Cohance Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting
- Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection |SUBJECT: General Updates
- Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026. |SUBJECT: Committee Meeting Updates
- Cohance Lifesciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Press Release ". |SUBJECT: Press Release
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹438.17
- Risk regime: Higher Price Risk

### Support levels
- 429.1
- 417.4
- 391.05

### Resistance levels
- 442.5203125
- 456.3
- 475.35

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -0.44% |
| return_10 | -4.96% |
| return_1m | -3.78% |
| return_1y | -52.01% |
| return_20 | -7.90% |
| return_3m | +5.85% |
| return_5 | -1.64% |
| return_6m | +43.02% |
| return_since_start | -59.01% |
| return_ytd | -16.33% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -74.76% |
| annualized_volatility | +47.33% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Contraction and Rising Other Expenses Drive Quarterly Loss

Cohance Lifesciences reported its lowest quarterly revenue in recent periods, resulting in a shift from profit to loss for the quarter ended June 30, 2026. Revenue fell 23.1% year-over-year to ₹422.26 crore. While finance costs decreased slightly, other expenses rose 7.7% compared to the same period last year. This combination produced a pre-tax loss of ₹42.87 crore and a net loss of ₹45.19 crore, reversing the ₹46.40 crore profit recorded a year earlier. A tax expense of ₹2.32 crore during the loss-making quarter further widened the net loss.

## Revenue Volatility and Sequential Contraction

Revenue from operations stood at ₹422.26 crore, a 31.8% decrease from the previous quarter (₹619.12 crore) and a 23.1% decrease from the year-ago quarter (₹549.31 crore). The quarterly data shows significant variability: the second quarter of the prior fiscal year recorded ₹1,104.88 crore, roughly double the surrounding quarters, while the current quarter represents the lowest point in the series. The sequential decline of ₹196.86 crore brought revenue to the bottom of the observed range.

## Other Expenses and Operating Leverage

Other expenses totaled ₹167.86 crore, a 7.7% increase from ₹155.84 crore in the year-ago quarter, even as revenue contracted. As a result, other expenses as a percentage of revenue expanded from 28.4% to 39.8%. Sequentially, other expenses declined 5.2% from ₹177.00 crore in the prior quarter, but this reduction was insufficient to offset the 31.8% drop in revenue. Finance costs decreased 26.7% sequentially to ₹6.74 crore, representing approximately 1.6% of revenue and providing only a minor offset to the profitability pressure.

## Profitability Swing and Tax Expense

Profit Before Tax swung from a profit of ₹19.91 crore in the preceding quarter to a loss of ₹42.87 crore. Compared to the year-ago quarter, PBT moved from a profit of ₹62.76 crore to a loss of ₹42.87 crore. Despite recording a pre-tax loss, the company recognized a tax expense of ₹2.32 crore, which increased the absolute size of the net loss to ₹45.19 crore. In the year-ago quarter, the effective tax rate was approximately 26%, and in the fourth quarter of the prior fiscal year, the tax-to-profit ratio exceeded 58%.

## Per-Share Impact

Basic Earnings Per Share moved from ₹1.28 in the year-ago quarter to a loss of ₹0.63. Diluted EPS followed a similar path, declining from ₹1.27 to a loss of ₹0.65. Paid-up equity share capital remained constant at ₹38.26 crore (face value ₹1 per share) across the reporting periods, indicating no equity issuances or buybacks occurred. The per-share loss reflects the consolidated earnings result, calculated using weighted average shares rather than a simple division of net loss by paid-up capital.

## Management Commentary

Cohance Lifesciences reported a weak Q1 FY27, as guided, with consolidated revenue down 23.1% YoY to ₹4,223 Mn and adjusted EBITDA of ₹92 Mn (2.2% margin), reflecting shipment phasing, negative operating leverage, and subsidiary consolidation. Management expects sequential improvement from Q2 and a return to year-on-year growth in H2 FY27, supported by secured orders, scheduled deliveries, and progress across the late-stage pipeline. Key strategic actions include building an integrated nucleic-acid business with a clear path to full ownership of Sapala and repositioning Agrochemicals towards an innovator-product-led portfolio. The API+ business remained resilient with a healthy order book, while the USFDA inspection at Pashamylaram concluded with five addressable observations, none related to data integrity. The balance sheet remains net cash positive at ₹2,512 Mn, with free cash flow of ₹1,063 Mn generated during the quarter.

## Key Takeaway

The quarter’s loss resulted from a sharp 23% year-on-year revenue decline to ₹422.26 crore, while other expenses rose 7.7% to ₹167.86 crore, expanding the other-expense-to-revenue ratio from 28.4% to 39.8%. The resulting pre-tax loss of ₹42.87 crore and net loss of ₹45.19 crore reversed the prior-year profit, with a tax expense further widening the net loss.

### Ratios

## Official filings

- 2026-09-18 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_18092026183054_Cohance_CCPS_Disclosure_18Sep2026.pdf)
- 2026-09-17 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_17092026125044_Cohance_Disclosure_Investor_Meet.pdf)
- 2026-09-17 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_17092026195109_Cohance_AGM_disclosure_17Sep26_.pdf)
- 2026-09-04 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_05092026003353_Cohance_USFDA_disclosure_5Sept26.pdf)
- 2026-09-03 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_03092026195023_Cohance_Disclosure_Reg_30_3Sep2026_.pdf)
- 2026-09-03 — Press Release: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_03092026200923_Cohance_Press_Release_3Sep2026_.pdf)
- 2026-08-27 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_27082026160540_Cohance_SE_Newespaper_Advertisment.pdf)
- 2026-08-27 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_27082026172145_Cohance_-_Intimation_of_conferences.pdf)
- 2026-08-26 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_26082026194650_Cohance_SE_intimation_on_notice_on_AGM.pdf)
- 2026-08-26 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_26082026195608_Cohance_Integrated-Annual-Report_2026.pdf)
- 2026-08-26 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_26082026195937_Cohance_BRSR_2026.pdf)
- 2026-08-26 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_17775_WebXMLFile_20260826_223409524.xml)
- 2026-08-25 — Annual Report: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_30685_COHANCE_2025_2026_A_19070825_26082026195427.pdf)
- 2026-08-17 — Regulatory Filing: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COHANCE_08172026151822_52658.zip)
- 2026-08-13 — Credit Rating Update: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_13082026122952_Cohance_Crisil_rating_withdraw_13Aug26_.pdf)
- 2026-08-11 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_11082026171154_Cohance_Q1FY27_Concall_transcript.pdf)
- 2026-08-06 — Generic Announcement: Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its unaudited financial results for the quarter ended June 30, 2026, on August 6, 2026. The company reported total income from operations of ₹359.89 crore on a standalone basis and ₹422.26 crore on a consolidated basis. Net profit after tax was ₹1.41 crore standalone and ₹46.40 crore consolidated. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06082026185828_Cohance_Newspaperadvt_06082026.pdf)
- 2026-08-05 — Generic Announcement: On August 5, 2026, Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved a reorganization at its subsidiary, Sapala Organics Private Limited, and the convening of the 8th Annual General Meeting on September 17, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_05082026174607_Cohance_Outcome_BM_5Aug26.pdf)
- 2026-08-05 — Press Release: Cohance Lifesciences Limited announced unaudited financial results for the quarter ended June 30, 2026, reporting revenue of ₹4,223 million, a 23.1% year-on-year decrease. Adjusted EBITDA was ₹92 million. Capital expenditure was approximately ₹598 million, and consolidated net cash stood at ₹2,512 million as of June 30, 2026. The company highlighted strategic initiatives including integrating its nucleic-acid business and repositioning its Agrochemicals portfolio. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_05082026180608_Cohance_Press_Release_5Aug26.pdf)
- 2026-08-05 — Earnings Presentation: Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has released its investor presentation for the quarter ended June 30, 2026, detailing financial results and strategic initiatives. The company reported Q1 FY27 revenues of INR 4,223 million, a 23.1% year-over-year decline, attributed to shipment phasing, product mix, and subsidiary consolidation. Adjusted EBITDA was INR 92 million, with margins at 2.2%. Strategic priorities include integrating the nucleic-acid business around Sapala Organics, with a defined path to full ownership, and repositioning Agrochemicals. The company expects sequential improvement from Q2 and growth weighted towards the second half of FY27. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_05082026180833_Cohance_Investor_Presentation_5Aug26.pdf)
- 2026-08-05 — Generic Announcement: Cohance Lifesciences Limited announced the completion of a USFDA inspection at its Pashamylaram, Hyderabad facility, which took place from July 27, 2026, to August 5, 2026. The inspection resulted in a Form FDA 483 with five observations, none of which pertain to data integrity. The company is assessing these observations and preparing a response with corrective actions for submission to the USFDA. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_05082026184250_Cohance_USFDA_disclosure_05082026.pdf)
- 2026-08-05 — Generic Announcement: Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has uploaded an audio recording of its conference call for the quarter ended 30 June 2026. The call took place on 5 August 2026 and the recording is available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_05082026214319_Cohance_concall_audiolink05082026.pdf)
- 2026-07-23 — Generic Announcement: Cohance Lifesciences Limited will host a conference call for investors and analysts on August 5, 2026, at 6:30 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company's senior management will present the results, followed by a Q&A session. The results are scheduled to be announced earlier on the same day. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_23072026132445_Cohance_Q1_Concal_Invite_05082026.pdf)
- 2026-07-23 — Generic Announcement: On July 23, 2026, Cohance Lifesciences Limited's Nomination and Remuneration Committee approved the grant of up to 1,97,48,317 stock options under the new ESOP 2026 and 174,843 stock options under the existing ESOP 2023. The committee also approved the allotment of 30,190 equity shares upon exercise of options under ESOP 2023 and the cancellation of 1,87,703 stock options previously granted under ESOP 2023. The company also noted in-principle approvals from BSE Limited and National Stock Exchange of India Limited for the ESOP 2026, received on July 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_23072026212536_Cohance_SE_disclosure_ESOP_23Jul2026.pdf)
- 2026-07-23 — Official Filing: Cohance Lifesciences Limited will hold a board meeting on August 5, 2026, to consider unaudited quarterly financial results for the period ended June 2026. The trading window for the company will be closed from July 1, 2026, to August 8, 2026.

## News and market events

- 2026-09-08 — MONEYCONTROL: **Axis AMC PMS fund dumps DMart on q-comm squeeze, exits REC over state discom credit risks** — Axis AMC, PMS, Alternates, Axis brokerage. portfolio management — [Source](https://www.moneycontrol.com/news/business/markets/axis-amc-pms-fund-dumps-dmart-on-q-comm-squeeze-exits-rec-over-state-discom-credit-risks-14024970.html)
- 2026-09-07 — BUSINESSTODAY: **Top stocks in news: JSW Steel, TMCV, Mazagon, RVNL, Lupin, Molbio, Purple Style, HEG, Lemon Tree** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, JSW Steel, Tata Motors, TMCV, Mazagon Dock Engineering, RVNL, Rail Vikas Nigam, Lupin, Molbio Diagnostics, Purple Style Labs, HEG, Lemon Tree Hotels, Shiprocket, Behari Lal Engineering, Mazagon Dock Shipbuilders, Lemon Tree Hotels, Cohance Lifesciences, Urban Enviro Waste Management, Brigade Enterprises, Price Focus, Nava, Jayaswal Neco Industries — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-jsw-steel-tmcv-mazagon-rvnl-lupin-molbio-purple-style-heg-lemon-tree-blel-553519-2026-09-07)
- 2026-09-04 — The Hindu: **Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC** — Cohance Lifesciences invests $18 million in NJ Bio and Aruka Bio to enhance its antibody-drug conjugate strategy and partnerships. — [Source](https://www.thehindu.com/business/industry/cohance-lifesciences-investing-18-million-in-nj-bio-aruka-bio-to-sharpen-focus-on-adc/article71427415.ece)
- 2026-09-04 — MONEYCONTROL: **Price Action: WeWork India rises 3% on solar plant approval; Shanthi Gears jumps 5% after CFO appointment** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/stocks/price-action-wework-india-rises-3-on-solar-plant-approval-shanthi-gears-jumps-5-after-cfo-appointment-14022429.html)
- 2026-09-04 — The Hindu: **Stocks in focus: IEX, PowerGrid, RVNL, APSEZ, Bharat Forge, HEG, brokerage stocks,Cipla among dozen stocks will be in focus** — IEX logs record August volumes; HEG renamed as scheme takes effect — [Source](https://www.thehindubusinessline.com/markets/stocks-in-focus-iex-powergrid-rvnl-apsez-bharat-forge-heg-brokerage-stockscipla-among-dozen-stocks-will-be-in-focus/article71426821.ece)
- 2026-08-24 — Economic Times: **Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?** — Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity. — [Source](https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms)
- 2026-08-18 — MONEYCONTROL: **Cohance's Umang Vohra says the worst is over; market looks for signs of recovery** — Umang Vohra, Cohance Lifesciences, Advent International, Advent, Suven Pharma, CDMO, API, Vivek Sharma, NJ Bio, ADCs — [Source](https://www.moneycontrol.com/news/business/cohance-s-umang-vohra-says-the-worst-is-over-market-looks-for-signs-of-recovery-14009140.html)
- 2026-08-06 — MONEYCONTROL: **Reduce Cohance Lifesciences; target of Rs 365: ICICI Securities** — ICICI Securities, reduce, Cohance Lifesciences, Recommendation — [Source](https://www.moneycontrol.com/news/business/stocks/reduce-cohance-lifesciences-target-of-rs-365-icici-securities-13996415.html)
- 2026-08-06 — The Hindu: **Sensex today | Stock Market Live: Sensex up 200 pts, Nifty holds 24,600 in choppy trade; Reliance, BEL lead gainers; TTK Healthcare shares jump 15% on strong Q1** — Sensex, Nifty, Share Prices LIVE: Benchmark indices edged higher at the open ‌on Thursday, supported by hopes of a diplomatic breakthrough ⁠in the Middle East and a better-than-expected June-quarter earnings season. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-6-august-2026/article71309748.ece)
- 2026-08-06 — MONEYCONTROL: **Buzzing Stocks: Kolte-Patil Developers jumps 5% on project wins; Godrej Agrovet slips after weak Q1 earnings** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-kolte-patil-developers-jumps-5-on-project-wins-godrej-agrovet-slips-after-weak-q1-earnings-13995977.html)
- 2026-08-06 — MONEYCONTROL: **Cohance Life shares in focus after USFDA flags five observations; Q1 loss widens** — Cohance Lifesciences,Cohance Lifesciences share price live today — [Source](https://www.moneycontrol.com/news/business/markets/cohance-life-shares-in-focus-after-usfda-flags-five-observations-q1-loss-widens-13995635.html)
- 2026-08-05 — The Hindu: **Cohance Lifesciences reports ₹45.19 crore loss in Q1 on lower revenue** — Cohance Lifesciences reports ₹45.19 crore Q1 loss due to lower revenue, despite growth in subsidiaries and API performance. — [Source](https://www.thehindu.com/business/industry/cohance-lifesciences-reports-4519-crore-loss-in-q1-on-lower-revenue/article71310648.ece)
- 2026-08-05 — CNBC-TV18: **Stocks to Watch for August 6: Cummins India, Biocon, PB Fintech and more** — Stocks such as Navin Fluorine International, Cummins India, PB Fintech, JK Lakshmi Cement, Neuland Laboratories and Aster DM Quality Care will be in focus on Thursday after reporting their June-quarter earnings post market hours on Wednesday. Investors will also track companies scheduled to announce their June-quarter results during the day for stock-specific cues. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-6-cummins-india-biocon-pb-fintech-and-more-19962532.htm)
- 2026-08-05 — CNBC-TV18: **Stocks to Watch for August 6: Cummins India, Biocon, PB Fintech and more** — Stocks such as Navin Fluorine International, Cummins India, PB Fintech, JK Lakshmi Cement, Neuland Laboratories and Aster DM Quality Care will be in focus on Thursday after reporting their June-quarter earnings post market hours on Wednesday. Investors will also track companies scheduled to announce their June-quarter results during the day for stock-specific cues. — [Source](https://www.cnbctv18.com/market/stocks-to-watch-for-august-6-cummins-india-biocon-pb-fintech-and-more-19962532.htm)
- 2026-08-05 — CNBC-TV18: **Cohance Lifesciences’ Hyderabad plant gets USFDA observations: What it means for the pharma maker** — Cohance Lifesciences received five observations from the USFDA after an inspection of its Hyderabad manufacturing facility. The company said the findings do not involve data integrity issues and it is working on corrective measures to address the regulator’s concerns. — [Source](https://www.cnbctv18.com/business/companies/cohances-hyderabad-facility-gets-five-usfda-observations-after-inspection-19962649.htm)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)

## Business profile

**Strategic vision:** Global CDMO for pharmaceutical and chemical product lifecycles.

### Business segments
- **Small Molecule API:** Offers end-to-end solutions for Small Molecule API development and manufacturing, from early-phase process design to commercial supply, handling complex and high-potency APIs.
- **Nucleic Acid Chemistry:** Provides custom nucleic acid synthesis, process development, scale-up, and GMP manufacturing for therapeutic companies developing drugs based on oligonucleotides and other emerging modalities.
- **Generic APIs:** Operates an integrated Generic API platform serving a global customer base with over 50 molecules across various therapeutic areas, supported by 8 cGMP facilities.
- **Specialty Chemicals:** Delivers advanced solutions in Agrochemicals and Performance Chemicals, integrating scientific expertise, scalable manufacturing, and regulatory excellence for various industries.

### Competitive strengths
- Expertise in handling complex, sensitive, and high-potency APIs.
- Robust safety assessments and regulatory compliance.
- Extensive experience in nucleic acid chemistry and custom synthesis.
- Global regulatory expertise and a reliable supply network for generic APIs.
- Integration of scientific expertise, scalable manufacturing, and regulatory excellence in specialty chemicals.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/cohance
Markdown representation: https://faxioms.com/stocks/cohance?render=md